Buscar
COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos?
(Elsevier, 2020)
La pandemia SARS-CoV-2 es una emergencia sanitaria global y necesitamos conocer
más sobre ella.
Los pacientes con riesgo cardiovascular y renal previo se han identificado como especialmente
vulnerables para una mayor ...
Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study
(BMC, 2018-09-04)
Background:
Despite the epidemiological evidence about the relationship between diabetes, mortality and cardiovascular disease, information about the population impact of uncontrolled diabetes is scarce. We aimed to ...
Dislipidemia y riesgo vascular. Una revisión basada en nuevas evidencias
(Elsevier, 2014-01)
La dislipidemia es uno de los principales factores de riesgo de cardiopatía isquémica, primera causa de mortalidad en el mundo. Realizar una detección temprana y una intervención terapéutica precoz son elementos clave a ...
Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease
(2021-03-25)
Background:
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence ...
Magnitude of pharmacological nonadherence in hypertensive patients taking antihypertensive medication from a community pharmacy in Spain
(Academy of Managed Care Pharmacy, 2014-12)
BACKGROUND: The most common factor associated with poor control of
hypertension is treatment nonadherence to antihypertensive drug therapy.
OBJECTIVE: To measure drug nonadherence and associated factors in
pharmacologically ...
Documento de consenso para la determinación e informe del perfil lipídico en laboratorios clínicos españoles. ¿Qué parámetros debe incluir un perfil lipídico básico?
(Elsevier, 2023)
Las enfermedades cardiovasculares (ECV) siguen siendo la principal causa de muerte en nuestro país. El control adecuado de las alteraciones del metabolismo lipídico es un reto clave en prevención cardiovascular que está ...
Non-compliance and therapeutic inertia: two unanswered questions in clinical practice
(Informa Healthcare, 2014)
Is the Physician’s Behavior in Dyslipidemia Diagnosis in Accordance with Guidelines? Cross-Sectional Escarval Study
(Public Library of Science, 2014)
Background:
Clinical inertia has been defined as mistakes by the physician in starting or intensifying treatment when
indicated. Inertia, therefore, can affect other stages in the healthcare process, like diagnosis. The ...
Fisiopatología renal y mecanismos farmacológicos de nefroprotección
(Elsevier, 2023-06)
Son varios los factores de riesgo que pueden afectar la progresión de la enfermedad
renal crónica (ERC). La hipertensión arterial, la proteinuria, la obesidad, la hipertensión
intraglomerular, el tabaco y el control ...
Overview of guidelines for the management of dyslipidemia: EU perspectives
(Dove Press, 2016-09)
Modern medicine is characterized by a continuous genesis of evidence making
it very difficult to translate the latest findings into a better clinical practice. Clinical practice
guidelines (CPG) emerge to provide ...